Product image of Mitomycin Medac (Mitomycin) supplied by GNH India

Mitomycin Medac

Active Ingredient:
Mitomycin
Origin:
EU

Mitomycin Medac (Mitomycin)

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic antibiotic presented as a sterile solution for intravenous and intravesical use. It is employed in the treatment of certain solid tumours, most notably bladder cancer, and is administered by qualified healthcare professionals.

GNH India supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Manufacturer / TM Owner

Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mitomycin is an antineoplastic agent used in several solid‑tumour indications.

  • Bladder cancer: intravesical administration reduces tumour recurrence after transurethral resection.
  • Gastric cancer: intravenous therapy contributes to tumour shrinkage in combination regimens.
  • Pancreatic cancer: used as part of multi‑drug protocols for advanced disease.
  • Anal canal carcinoma: administered intravenously to improve local control when combined with radiotherapy.
  • Head and neck squamous cell carcinoma: adjunctive intravenous use in selected cases.

How It Works

  • Mitomycin exerts its antitumour activity by forming covalent cross‑links between DNA strands. The drug undergoes enzymatic reduction within hypoxic tumour cells, generating reactive intermediates that bind to the N2 position of guanine residues. This cross‑linking blocks DNA replication and transcription, ultimately triggering apoptosis of rapidly proliferating cancer cells.

Side Effects

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea and vomiting: mild to moderate gastrointestinal upset.
  • Myelosuppression: reduced white blood cells, platelets, and red cells.
  • Hematuria: blood in urine, especially after intravesical use.
  • Fatigue: generalized tiredness during treatment cycles.
  • Skin erythema: localized redness at injection sites.

Serious or Rare Side Effects

  • Pulmonary fibrosis: progressive scarring of lung tissue.
  • Severe bone marrow failure: pancytopenia requiring transfusion.
  • Renal toxicity: impaired kidney function, especially with high cumulative doses.
  • Severe allergic reactions: anaphylaxis or hypersensitivity.
  • Secondary malignancies: rare development of new cancers after prolonged exposure.

Precautions & Warnings

Mitomycin requires careful monitoring and adherence to safety guidelines.

  • Renal function: assess creatinine clearance before each dose.
  • Hepatic function: evaluate liver enzymes to adjust dosing if needed.
  • Hematologic status: perform complete blood counts prior to therapy.
  • Pregnancy and lactation: avoid use; discuss risks with a specialist.
  • Concomitant nephrotoxic agents: limit combined exposure.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mitomycin may interact with other medicines, influencing efficacy or toxicity.

Major Interactions (Avoid)

  • High‑dose cyclophosphamide: additive bone‑marrow suppression.
  • Nephrotoxic antibiotics (e.g., aminoglycosides): increased renal injury risk.
  • Anticoagulants (warfarin): heightened bleeding tendency.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may exacerbate renal dysfunction.
  • Antifungal agents (e.g., fluconazole): potential alteration of mitomycin metabolism.
  • Radiotherapy: combined use may amplify tissue toxicity.

Frequently Asked Questions

Mitomycin Medac is an antineoplastic antibiotic indicated for the treatment of certain solid tumours, most prominently bladder cancer when given intravesically, as well as gastric, pancreatic, anal canal and selected head‑and‑neck cancers when administered intravenously as part of combination regimens.

Mitomycin is reduced inside hypoxic tumour cells to generate reactive intermediates that covalently cross‑link DNA strands. This cross‑linking blocks DNA replication and transcription, leading to cell cycle arrest and apoptosis of rapidly dividing cancer cells.

The dose of Mitomycin Medac is individualized by the prescribing oncologist based on the specific cancer type, treatment protocol, patient weight, renal and hepatic function, and prior therapy. Exact dosing regimens are not disclosed publicly.

Mitomycin is classified as contraindicated in pregnancy and breastfeeding because it can cross the placenta and be excreted in breast milk, posing a risk of fetal or infant toxicity. Women of child‑bearing potential should use effective contraception and discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Mitomycin differs from many modern targeted therapies by acting as a DNA‑cross‑linking agent rather than a kinase inhibitor. Its efficacy is well‑established in bladder cancer and certain solid tumours, but it may have a higher risk of bone‑marrow suppression and pulmonary toxicity compared with some newer agents.

Mitomycin Medac should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. The product must be kept in its original packaging until use to maintain stability and sterility.

The drug is supplied as a sterile solution for intravenous infusion or intravesical instillation. Intravenous dosing is performed by a qualified healthcare professional in a clinical setting, while intravesical administration involves instilling the solution directly into the bladder after tumor resection.

Serious risks include severe bone‑marrow suppression (pancytopenia), pulmonary fibrosis, renal toxicity, and rare secondary malignancies. Patients should be monitored closely for signs of infection, bleeding, respiratory difficulty, and changes in kidney function throughout therapy.

Mitomycin Medac is contraindicated in patients with known hypersensitivity to mitomycin or related compounds, those with severe renal or hepatic impairment, pregnant or nursing women, and individuals with uncontrolled infections or active severe bone‑marrow failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mitomycin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT